Drug safety and regulatory intelligence for QPPV, Signal, Labeling, PV Ops, and Device Vigilance — daily briefings with operational next steps.
Need customization?Map custom PV workflows, roles, and reporting needs with us.Get in touchTopics we cover
Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.
MAHs and trial sponsors must align their safety monitoring and data collection workflows with the new GCP principles established in ICH E6(R3) Annex 2.
MAHs must update their application submission procedures to utilize the SUGAM portal for all relevant post-approval changes from June 24, 2026.
Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.
MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.
Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.
Tga update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.
